WO1994023694A1 - Cosmetic composition containing ceramide precursors - Google Patents
Cosmetic composition containing ceramide precursors Download PDFInfo
- Publication number
- WO1994023694A1 WO1994023694A1 PCT/EP1994/001117 EP9401117W WO9423694A1 WO 1994023694 A1 WO1994023694 A1 WO 1994023694A1 EP 9401117 W EP9401117 W EP 9401117W WO 9423694 A1 WO9423694 A1 WO 9423694A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ceramide
- skin
- composition according
- precursor
- ceramide pathway
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
Definitions
- the invention relates to skin-conditioning compositions and methods. It is particularly concerned with the stimulation of ceramide production in the epidermis, leading to an increase in the level of these lipid materials in the stratum corneum of the skin.
- the composition is also suitable for topical application to the hair and the nails.
- the stratum corneum which is the outermost layer of the mammalian skin, contains intercellular lipids consisting predominantly of ceramides, cholesterol and fatty acids. From studies involving lipid depletion of the corneum by solvent extraction and from enzyme inhibition studies, ceramide in particular has been shown to be essential for the barrier function of the stratum corneum.
- the epidermis In normal skin, if there is perturbation of the barrier function, the epidermis normally re-synthesises the deficient lipids by inducing the expression or activation of the appropriate enzymes. However, under certain conditions, a reduced capacity for re-synthesis of the lipids may occur. This is especially so with elderly subjects, whose stratum corneum ceramide level is in any case reportedly lower than that of younger subjects.
- the present invention is based upon the concept of stimulating the synthesis of ceramides in the epidermis by the topical application of precursors thereof in the biosynthetic pathway and/or by stimulation of the activity of enzymes responsible for catalysing the steps in the biosynthetic pathway that yields ceramide (as described later in this specification) .
- ceramide in the epidermis can be achieved by a variety of biochemical pathways, for example, those shown in Figure 1.
- the invention is accordingly concerned with the use of one or more of these ceramide pathway intermediates, following topical application, in enhancing the quality and condition of human skin, especially the water barrier properties thereof, in particular by increasing the rate of ceramide biosynthesis in the epidermis.
- composition suitable for topical application to human skin which comprises :
- the invention is also concerned with a method of treating skin, particularly dry and aged skin, with topically applied ceramide pathway intermediate, or a precursor thereof or mixtures thereof, in order to maintain or repair the skin barrier which controls moisture loss from the skin.
- the invention is also concerned with the use of one or more ceramide pathway intermediates, or precursors thereof or mixtures thereof in maintaining or enhancing the skin barrier function which controls moisture loss from the skin and in the treatment of skin to reduce or delay the development of wrinkles associated with advancing age, or with sun-induced skin ageing.
- the invention is also concerned with the use of at least 0.0001% by weight based on the total composition, of a ceramide pathway intermediate in a composition suitable for topical application to human skin comprising a major proportion of a cosmetically acceptable vehicle for the ceramide pathway intermediate.
- composition according to the invention comprises in its simplest form a ceramide pathway intermediate or a precursor thereof, or mixtures thereof together with a cosmetically acceptable vehicle, the composition being suited for topical application to human skin.
- the primary function of the said intermediate or precursor thereof is to stimulate the synthesis of ceramide in the epidermis which then leads to higher ceramide levels in the stratum corneum.
- the water permeability barrier function of the skin is thereby improved and the ability of the skin to retain moisture consequently enhanced.
- 3-ketosphingosine is converted firstly to sphinganine and then secondly to sphingosine, and then to N-acyl sphingosine (Ceramide (B) ) .
- 3-ketosphinganine is converted to sphinganine in the presence of NADPH- dependant reductase, as occurs in Ceramide Pathway I, but then sphinganine is converted firstly to sphingosine, and secondly to phytosphingosine and then to N- acylphytosphingosine (Ceramide (C) ) .
- Ceramides produced via ceramide pathways I, II and III are likely to be structurally different from each other and for this purpose are designated Ceramides (A) , (B) and (C) .
- the conversion of palmitoyl-CoA and serine to 3-ketosphinganine in the presence of serine palmitoyltransferase represents the rate limiting step, ie the step which limits the formation of ceramide in the skin and other tissues. Accordingly, in order to enhance the rate at which ceramide is formed, particularly in the skin, it is preferred to deliver to the skin an effective amount of a precursor of ceramide which enters one or more of the Ceramide Pathways distal to this rate limiting step.
- ceramide The rate of formation of ceramide can thus be enhanced by providing as precursors sphingoid bases, typical examples of which are sphinganine, sphingosine and phytosphingosine and derivatives thereof in accordance with structure (1) : where X is represented by
- R 1 , R 2 , R 3 and R 5 are each individually represented by H- , CH 3 (CH 2 ) n -
- n 0, or an integer of from 1 to 10
- R 4 is CH,(CH 2 ) where m is an integer of from 1 to 21.
- ceramide pathway intermediates includes: sphinganine, sphingosine and phytosphingosine and their respective N-acyl, O-acyl and N-alkyl derivatives.
- a particularly preferred ceramide pathway intermediate is tetraacetyl phytosphingosine having the structure (2) :
- Particularly preferred derivatives of sphinganine are N-acetyl sphinganine having the structure (3) :
- N-methyl sphinganine having the structure (4)
- the acyl substituent is suitably a C-. 16 acyl group preferably acetoxy.
- the pathway intermediate may be acylated at teh N-atom and one or more of hte oxygen atom present.
- the alkyl substituent is suitably C-_- b , preferably
- the nitrogen atom may be mono- or di -alkylated .
- N, N'-dimethylsphinganine having the structure ( 5 )
- Particular preferred derivatives of sphingosine are -acetylsphingosine having the structure (6) :
- N-methyl sphingosine having the structure (7) : - S
- precursors of ceramide synthesis that occur proximal to the rate limiting step in the ceramide pathway.
- These precursors are preferably palmitoyl CoA and serine which together are converted to 3-ketosphinganane by the enzyme serine palmitoyltransferase .
- the amount of a selected ceramide pathway intermediate including precursors thereof or mixture thereof that should be incorporated in the composition according to the invention is from 0.0001 to 10%, preferably from 0.1 to 5% and ideally from 0.05 to 2% by weight of the composition.
- composition according to the invention also comprises a solid, semi-solid or liquid cosmetically and/or physiologically acceptable vehicle, to enable the ceramide pathway intermediate to be conveyed to the skin at an appropriate dilution.
- vehicle will depend upon the method chosen for topical administration of the composition.
- the vehicle can itself be inert or it can possess physiological or pharmaceutical benefits of its own.
- a vehicle for this purpose presents a wide range of possibilities depending on the required product form of the composition. Suitable vehicles can be classified as described hereinafter.
- vehicles are substances which can act as diluents, dispersants, or solvents for the ceramide pathway intermediate which therefore ensure that they can be applied to and distributed evenly over the skin, hair or nails at an appropriate concentration.
- the vehicle is preferably one which can aid penetration of the ceramide pathway intermediate into the skin to enable it more readily to influence the skin condition.
- compositions according to the invention can include water as a vehicle, and/or at least one cosmetically acceptable vehicle other than water.
- Vehicles other than water can include liquid or solid emollients, solvents, humectants, thickeners and powders. Examples of each of these types of vehicle, which can be used singly or as mixtures of one or more vehicles, are as follows:
- Emollients such as stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl aicohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di-n-butyl sebacate, isopropyl yristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, evening primrose oil
- Propellants such as propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide;
- Solvents such as ethyl alcohol, methylene chloride, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxide, dimethyl formamide, tetrahydrofuran;
- Powders such as chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate, ethylene glycol distearate;
- the cosmetically acceptable vehicle will usually form from 10 to 99.999%, preferably from 10 to 99% and most preferably from 50 to 99% by weight of the composition, and can, in the absence of other cosmetic adjuncts, form the balance of the composition.
- the ceramide pathway intermediates and precursors thereof are preferably accompanied by saturated or unsaturated, straight or branched chain fatty acids or their esters, particularly their coenzyme A derivatives, or adenosine monophosphate derivatives, or preferably alpha-, beta or omega hydroxylated straight or branched chain fatty acids and esters thereof, especially the omega hydroxy linoleoyl ester.
- the amount of selected ceramide pathway adjuncts, when employed, can be similar to that of the ceramide pathway intermediate or precursor thereof .
- composition according to the invention can also optionally comprise a penetration enhancer which can potentiate the benefit of the ceramide pathway intermediate or precursor thereof by improving its delivery through the stratum corneum to its site of action in the epidermis.
- a penetration enhancer which can potentiate the benefit of the ceramide pathway intermediate or precursor thereof by improving its delivery through the stratum corneum to its site of action in the epidermis.
- the penetration enhancer can accordingly function in a variety of ways. It can for example, improve the distribution of the ceramide pathway intermediate on the skin surface or, it can increase its partition into the skin from the composition when applied topically, so aiding its passage to its site of action. Other mechanisms enhancing the benefit of the ceramide pathway intermediate may also be involved.
- penetration enhancers examples include:
- the amount of penetration enhancer when employed in accordance with the invention, will normally be from 0.1 to 50%, preferably from 0.5 to 25% and most preferably from 0.5 to 10% by weight of the composition.
- composition according to the invention is an emulsion, in which case an oil or oily material will normally be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on the average hydrophillic-lyophilic balance (HLB) of the emulsifier employed.
- HLB hydrophillic-lyophilic balance
- composition according to the invention can optionally comprise one or more oils or other materials having the properties of an oil.
- oils examples include mineral oil and vegetable oils, and oil materials, such as those already proposed herein as emollients.
- oils or oily materials include silicone oils, both volatile and non-volatile, such as polydimethyl siloxanes.
- the oil or oily material when present for the purposes for forming an emulsion, will normally form up to 90%, preferably from 10 to 80% by volume of the composition.
- composition according to the invention can also optionally comprise one or more emulsifiers the choice of which will normally determine whether a water-in-oil or and oil-in-water emulsion is formed.
- the chosen emulsifier or emulsifiers should normally have an average HLB value of from 1 to 6.
- a chosen emulsifier or emulsifiers should have an average HLB value of >6.
- Suitable emulsifiers are set below in Table 1 in which the chemical name of the emulsifiers is given together with an example of a trade name as commercially available, and the average HLB value.
- PEG 200 monostearate Sorbitan monolaurate Arlacel 200 8.6 PEG 400 dioleate Tegester PEG 400-DO 8.8
- the amount of emulsifier or mixtures thereof, to be incorporated in the composition of the invention, when appropriate is from 1 to 50%, preferably from 2 to 20% and most preferably from 2 to 10% by weight of the composition.
- composition of the invention can also optionally comprise a high molecular weight silicone surfactant which can also act as an emulsifier, in place of or in addition to the optional emulsifier (s) already mentioned.
- a high molecular weight silicone surfactant which can also act as an emulsifier, in place of or in addition to the optional emulsifier (s) already mentioned.
- the silicone surfactant is a high molecular weight polymer of dimethyl polysiloxane with polyoxyethylene and/or polyoxypropylene side chains having a molecular weight from 10,000 to 50,000.
- the dimethyl polysiloxane polymer is conveniently provided as a dispersion in a volatile siloxane, the dispersion comprising, for example, from 1 to 20% by volume of the polymer and from 80 to 99% by volume of the volatile siloxane.
- the dispersion consists of a 10% by volume of the polymer dispersed in the volatile siloxane.
- Examples of the volatile siloxanes in which the polysiloxane polymer can be dispersed include polydimethyl siloxane (pentamer and/or hexamer) .
- a particularly preferred silicone surfactant is cyclomethicone and dimethicone copolyol, such as DC 3225C Formulation Aid available from DOW CORNING.
- Another is laurylmethicone copolyol, such as DC Q2-5200, also available from Dow Corning.
- the amount of silicone surfactant, when present in the composition will normally be up to 25%, preferably from 0.5 to 15% by weight of the emulsion.
- composition according to the invention optionally can also comprise a retinoid, such as retinoic acid or retinol (Vitamin A) and/or derivative thereof, further to enhance the benefits to skin of the ceramide pathway intermediate.
- a retinoid such as retinoic acid or retinol (Vitamin A) and/or derivative thereof, further to enhance the benefits to skin of the ceramide pathway intermediate.
- examples of derivatives of retinol include:
- the amount of retinoid, when present in the composition according to the invention is from 0.01 to 10% and preferably 0.1 to 5% by weight of the composition.
- composition according to the invention optionally can also comprise a tocopherol (vitamin E group) , as an antioxidant for the retinoid, when present in the composition, and to limit oxidative damage to skin.
- the vitamin E group comprises a-tocopherol, ⁇ -tocopherol, ⁇ - tocopherol and ⁇ -tocopherol .
- the amount of a tocopherol, when present in the composition according to the invention, is from 0.0001 to 20%, preferably from 0.0001 to 10% by weight of the composition.
- composition of the invention can also comprise water, usually up to 90%, preferably from 5 to 80% by volume. Water can function as the cosmetically acceptable vehicle.
- Examples of other cosmetic adjuncts which can optionally be employed in the composition according to the invention include preservatives, such as para-hydroxy benzoate esters; antioxidants, such as butyl hydroxy toluene; humectants, such as glycerol, sorbitol, 2-pyrrolidone-5- carboxylate, dibutylphthalate, gelatin, polyethylene, glycol, preferably PEG 200-600; buffers, such as lactic acid together with a base such as triethanolamine or sodium hydroxide; surfactants, such as glycerol ethers; ceramides of synthetic, animal or plant origin; pseudoceramides; phospholipids; vitamins, such as 1,25 dihydroxy cholecalciferol; waxes, such as beeswax, ozokerite wax, paraffin wax, plant extracts, such as Aloe vera, cornflower, witch hazel, elderflower, cucumber, thickeners; activity enhancers; colourants; perfumes; and sunscreen materials such as ultra
- the ceramide pathway intermediate is combined with ceramides, pseudoceramides, polyol fatty acid polyesters, sterols, particularly cholesterol, galactosyldiacyl-glycerols, glycosphingolipids, fatty acids and esters thereof and mixtures thereof and other ingredients, such as mevalonic acid, hexadecylsuccinic acid monobehenyl ester ethoxylate (7.3 EO) and/or derivatives thereof to produce a liposomal dispersion.
- Preferred ceramide pathway adjuncts include ceramides, cholesterol, cholesterol pathways intermediates or precursors thereof such as mevalonic acid and fatty acid pathway intermediates or precursors thereof such as acetic acid and malonic acid.
- a further preferred composition may also contain in combination with the ceramide pathway intermediate and optional additional ingredients disclosed above, an organic acid component chosen from hydroxy carboxylic acids, such as alpha, beta and omega hydroxyacids, especially glycolic acid, lactic acid and 2-hydroxyoctanoic acid, and keto carboxylic acids, esters thereof and mixtures thereof.
- an organic acid component chosen from hydroxy carboxylic acids, such as alpha, beta and omega hydroxyacids, especially glycolic acid, lactic acid and 2-hydroxyoctanoic acid, and keto carboxylic acids, esters thereof and mixtures thereof.
- the ceramide pathway intermediate is dissolved in squalene or squalane, optionally together with ceramides and other ingredients, such as mevalonic acid and malonic acid and/or derivatives thereof and formulated with volatile and non-volatile silicones to produce an anhydrous or nearly anhydrous single phase system.
- Cosmetic adjuncts can form the balance of the composition.
- composition according to the invention is preferably preserved in such a manner that it will enjoy an extended shelf life following manufacture and prior to sale and use.
- composition will have an indefinite shelf life.
- the ceramide pathway intermediate is likely to be prone to attack by bacteria, moulds and fungi and other microbial influences, particularly at pH values near that of the skin that characterise the preferred composition.
- the shelf-life of the composition can therefore be unacceptably short due to the biodegradation of the precursor unless steps are taken to preserve the composition.
- the composition should preferably be free, or substantially free, from viable microbial contaminants that are capable of resulting in microbial spoilage of the composition, and/or biodegradation of the precursor prior to topical application of the composition to mammalian skin or hair. It is to be understood, however, that the invention is also concerned with compositions, as herein defined, which may contain viable but dormant microorganisms, such as bacterial spores, provided that the conditions of preservation do not result in substantial proliferation of the microorganisms prior to use of the composition.
- composition according to the invention can be preserved by sterilisation to remove or kill substantially all viable microbial contaminants. This can be achieved for example by irradiation using a lethal dose of gamma rays, by heat sterilisation or by ultrafiltration using techniques that are well established in the pharmaceutical industry.
- composition according to the invention can also be preserved by including in it a chemical preservative which functions to prevent the growth of or kill bacteria, fungi or other microorganisms.
- Examples of chemical preservatives include ethanol, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, sodium propionate and the methyl, ethyl, propyl and butyl esters of p-hydroxybenzoic acid.
- the amount of chemical preservative that can be incorporated in the composition according to the invention will generally be from 0.05 to 5%, preferably from 0.1 to 2% by weight, the amount chosen being sufficient to arrest microbial proliferation.
- composition according to the invention can also be preserved by the inclusion of a water activity depressant such as glycerol, propylene glycol, sorbitol, sugars and salts, for examples alkali metal halides sulphates and carboxylates .
- a water activity depressant such as glycerol, propylene glycol, sorbitol, sugars and salts, for examples alkali metal halides sulphates and carboxylates .
- the invention also provides a process for preparing a composition according to the invention which comprises the steps of mixing an effective amount of a ceramide pathway intermediate, as herein defined, together with a cosmetically acceptable carrier for the intermediate.
- composition according to the invention is intended primarily as a product for topical application to human skin, for maintaining or enhancing the skin barrier function, particularly by stimulating the synthesis of ceramides.
- the composition is particularly useful for treating dry, ageing or damaged skin to reduce moisture loss, increase stratum corneum flexibility and to enhance the quality of skin.
- the composition can also be applied to the hair or nails.
- a small quantity of the composition for example from 1 to 5ml, is applied to exposed areas of the skin, hair or nails, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the area to be treated using the hand or fingers or a suitable device.
- the topical skin and/or hair and/or nail treatment composition of the invention can be formulated as a lotion having a viscosity of from 4,000 to 10,000 mPas, a fluid cream having a viscosity of from 10,000 to 20,000 mPas or a cream having a viscosity of from 20,000 to 100,000 mPas, or above.
- the composition can be packaged in a suitable container to suit its viscosity and intended use by the consumer.
- a lotion or fluid cream can be packaged in a bottle or a roll-ball applicator or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation.
- the composition When the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar.
- the invention accordingly also provides a closed container containing a cosmetically acceptable composition as herein defined.
- the biosynthesis of epidermal lipid, especially ceramides can be determined by the method described below. Results of ceramide biosynthesis from sphingosine as the ceramide pathway intermediate are also given.
- CPI CPI on lipid levels in the epidermis
- epidermis was isolated from the dermis by incubation in lOmM ethylenediaminetetraacetic acid solution at 37C for 30 minutes, and placed into 3ml of chloroform:methanol (2:1 v/v) solution for lipid extraction. After 18 hours 0.75ml of potassium chloride solution (0.88% w/v) was added with mixing which after centrifugation produced 2 liquid phases, an upper aqueous phase, and a lower organic phase containing the lipids. Beckman ReadySafe scintillation fluid (4ml) was added to lOO ⁇ l aliquots of the organic phase and counted in a Beckman LS 6000IC scintillation counter to determine the radioactivity present in the lipids .
- the plate was run successively with i) chloroform:methanol :acetone (76:20:4) to 15 and then 30mm, ii) chloroform:methanol:acetone (79:12.5:8.5) to 80mm, and finally iii) chloroform: ethyl acetate : diethyl ether:methanol (72:20:6:2) to 95mm.
- the plate was saturated with 15ml of acidic copper sulphate solution (10% copper sulphate, 8% phosphoric acid) for 1 minute and then the lipids charred by heating to 120C for 1 minute and then 160C for 10 minutes.
- Lipid bands were identified using authentic lipid standards (Sigma Chemical Co.) and were quantified by reflectance densitometric scanning at 420nm using a Shimadzu CS-9000 flying spot densitometer. Plates were then placed onto X-ray film
- Specific activity was calculated by dividing the radioactivity in each band by the mass of lipid in each band. Each lipid class was identified using authentic lipid standards.
- sphingosine on individual lipid classes was determined using HPTLC. For each lipid class examined sphingosine at O.O ⁇ mM increased the level of incorporation of radiolabelled acetate in comparison to the control (no sphingosine) .
- the specific activity (radioactivity/lipid mass) for each lipid class and the ratio of sphingosine treated to control is shown in Table 1.
- the ceramide and glucosylceramide class showed the greatest increase in radioactivity incorporation following sphingosine treatment followed by non-polar lipids and finally phospholipids and cholesterol sulphate.
- Sphingosine stimulates epidermal lipid biosynthesis, increasing the synthesis of all the lipid classes examined, but particularly the glucosylceramide and ceramide class .
- Human keratinocytes (ex clonetics were seeded in 6 well plates and allowed to reach 80% confluency after incubation in Keratinocyte Growth Medium (KGM ex clonetics, 0.15mM calcium) at 37C, 5% C02. Fresh medium was added containing radiolabelled lipid precursor (2 ⁇ Ci/ml of 1-14C acetic acid, sodium salt, 7.4 MBq/ml ex Amersham) and CPI (in 96% v/v ethanol vehicle) and incubated for 24 hours as above.
- Keratinocyte Growth Medium Keratinocyte Growth Medium (KGM ex clonetics, 0.15mM calcium) at 37C, 5% C02.
- Fresh medium was added containing radiolabelled lipid precursor (2 ⁇ Ci/ml of 1-14C acetic acid, sodium salt, 7.4 MBq/ml ex Amersham) and CPI (in 96% v/v ethanol vehicle) and incubated for 24 hours as above.
- TAPS glucosylceramide synthesis
- the organic phase was dried under nitrogen, and resuspended in 200 ⁇ L of chloroform.
- Different lipid classes were separated based upon their polarity, using aminopropyl column chromatography. 200 ⁇ L of lipid was eluted with successive washes of hexane, hexane:ethyl acetate (85:15 v/v) , and chloroform:isopropanol (2:1 v/v) . The fractions were then evaporated to dryness under nitrogen, and resuspended in lOO ⁇ L of chloroform:methanol (2:1 v/v) .
- HPTLC high performance thin layer chromatography
- TPS Tetra-acetyl phytosphingosine
- PHYT juniperic acid
- HA juniperic acid
- the combination of a sphingoid-base and an omega hydroxy fatty acid is capable of being used by keratinocytes to generate a ceramide 1-like molecule.
- TAPS tetraacetylphytosphinosine
- Solid phase extraction columns were used for preliminary lipid separation, followed by high performance thin layer chromatography (HPTLC) and densitometry for ceramide quantitation.
- the delipidized squames were incubated in protein extraction buffer, and protein content was determined by Pierce BCA assay.
- TAPS improves the levels of ceramides in the stratum corneum but has no effect on cholesterol and fatty acid levels, indicating its specificity as a ceramide precursor.
- This example illustrates a high internal phase water-ti -oil emulsion.
- a high internal phase water-in-oil emulsion having the following formulation was prepared:
- Example 2 also illustrates a high internal phase water- in-oil emulsion in which the formulation of Example 1 was prepared but with the following changes: i. liquid paraffin replaced the fully hydrogenated coconut oil, and
- This example also illustrates a high internal phase water- in-oil emulsion in which the formulation of Example 1 was prepared, except that sphingosine replaced phytosphingosine per se .
- This example illustrates an oil-in-water cream.
- This example also illustrates an oil-in-water emulsion, in which the formulation of example 4 was prepared, except that the sphinganine derivative having the structure (5) replaced the sphingosine derivative having the structure (8) .
- This example also illustrates an oil-in-water emulsion in which the formulation of example 4 was prepared, except that sphinganine replaced the sphingosine derivative having the structure (8) .
- This example illustrates an alcoholic lotion according to the invention.
- the lotion had the following formulation:
- This example illustrates an alcoholic lotion containing a sphingosine derivative of the invention.
- the lotion had the following formulations: w/w
- compositions according to the invention represent lotions which can be used in the treatment of dry skin:
- compositions according to the invention represent lotions which can be used in the treatment of dry skin: w/w
- This example illustrates a high internal phase water-in-oil emulsion.
- a high internal phase water-in-oil emulsion having the following formulation was prepared:
- This example illustrates an oil-in-water cream.
- This example illustrates an alcoholic lotion.
- the lotion had the following formulation:
- This example illustrates an alcoholic lotion containing a sphinganine derivative of the invention.
- the lotion had the following formulations : w/w
- Sphinganine derivative having the structure (3) 0.2 Dimethylsulphoxide 10 Ethanol 40 Antioxidant 0.1 Perfume qs Water to 100
- compositions according to the invention represen lotions which can be used in the treatment of dry skin:
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69407403T DE69407403T2 (en) | 1993-04-20 | 1994-04-07 | CERAMIDE PRECURSORS CONTAINING COSMETIC COMPOSITION |
EP94914359A EP0695167B1 (en) | 1993-04-20 | 1994-04-07 | Cosmetic composition containing ceramide precursors |
CA002159201A CA2159201C (en) | 1993-04-20 | 1994-04-07 | Cosmetic composition |
AU66774/94A AU684282B2 (en) | 1993-04-20 | 1994-04-07 | Cosmetic composition containing ceramide precursors |
JP52272494A JP3623793B2 (en) | 1993-04-20 | 1994-04-07 | Cosmetic composition comprising a ceramide precursor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9308103.2 | 1993-04-20 | ||
GB939308103A GB9308103D0 (en) | 1993-04-20 | 1993-04-20 | Cosmetic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994023694A1 true WO1994023694A1 (en) | 1994-10-27 |
Family
ID=10734120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/001117 WO1994023694A1 (en) | 1993-04-20 | 1994-04-07 | Cosmetic composition containing ceramide precursors |
Country Status (10)
Country | Link |
---|---|
US (1) | US5578641A (en) |
EP (1) | EP0695167B1 (en) |
JP (1) | JP3623793B2 (en) |
AU (1) | AU684282B2 (en) |
DE (1) | DE69407403T2 (en) |
ES (1) | ES2110747T3 (en) |
GB (1) | GB9308103D0 (en) |
NZ (1) | NZ265618A (en) |
WO (1) | WO1994023694A1 (en) |
ZA (1) | ZA942678B (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996016635A1 (en) * | 1994-11-28 | 1996-06-06 | Gist-Brocades B.V. | Topical application of ceramides |
EP0716589A1 (en) * | 1993-07-23 | 1996-06-19 | Morris Herstein | Cosmetic, skin-renewal stimulating composition with long-term irritation control |
WO1996037192A1 (en) * | 1995-05-26 | 1996-11-28 | Vesifact Ag | Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids |
DE19518815A1 (en) * | 1995-05-23 | 1996-11-28 | Beiersdorf Ag | Cosmetic or dermatological preparations containing alpha-hydroxy fatty acids |
US5607921A (en) * | 1994-01-31 | 1997-03-04 | L'oreal | Stabilized cosmetic or dermatological composition containing several precursors of the same active agent in order to maximize its release, and use thereof |
WO1997014401A1 (en) * | 1995-10-16 | 1997-04-24 | Kao Corporation | Skin and hair cosmetic compositions |
EP0790053A1 (en) * | 1996-02-15 | 1997-08-20 | L'oreal | Use of 2-amino-alkane-1,3-diol to reduce hairloss and/or to induce and stimulate hairgrowth |
WO1998013018A1 (en) * | 1996-09-27 | 1998-04-02 | Unilever Plc | Skin care composition containing an amide and retinol or retinyl ester |
EP0842655A2 (en) * | 1996-11-14 | 1998-05-20 | Kao Corporation | Water-in-oil type cosmetic emulsion containing amide derivatives |
FR2767056A1 (en) * | 1997-08-07 | 1999-02-12 | Oreal | USE OF A 2-AMINO-ALKANE POLYOL AS AN AGENT FOR TREATING THE SIGNS OF SKIN AGING |
US5932233A (en) * | 1996-11-07 | 1999-08-03 | Kao Corporation | Cosmetic compositions |
WO1999047114A1 (en) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Moisturizing compositions |
EP1287815A1 (en) * | 2001-08-31 | 2003-03-05 | Cosmoferm B.V. | Use of a sphingoid base for inhibiting ceramidase activity |
US7737186B2 (en) | 2002-03-01 | 2010-06-15 | Lvmh Recherche | Cosmetic use of phytosphingosine as slimming agent and cosmetic compositions comprising phytosphingosine |
CN102702894A (en) * | 2012-06-18 | 2012-10-03 | 中国船舶重工集团公司第七二五研究所 | Sphingosine derivative anti-fouling agent and preparation method thereof |
WO2013017361A1 (en) * | 2011-08-03 | 2013-02-07 | Evonik Goldschmidt Gmbh | Use of sphinganine to improve the visual appearance of skin and hair |
WO2013064388A3 (en) * | 2011-10-31 | 2013-07-11 | Evonik Industries Ag | Cosmetic formulation containing n-acyl-phytosphingosine |
WO2019185038A1 (en) * | 2018-03-29 | 2019-10-03 | 中国医学科学院基础医学研究所 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2737119B1 (en) * | 1995-07-25 | 1997-09-12 | Oreal | SILICONE COMPOSITION CONTAINING A WATER SENSITIVE ACTIVE INGREDIENT |
BR9804872A (en) * | 1997-05-02 | 1999-08-24 | Gist Brocades Bv | Antimicrobial compositions for typical use |
US5882665A (en) * | 1997-11-18 | 1999-03-16 | Elizabeth Arden Co., Division Of Conopco, Inc. | Phytosphingosine salicylates in cosmetic compositions |
KR100639531B1 (en) * | 1997-12-05 | 2006-10-27 | 코스모페름 베.파우 | Compositions comprising a combination of a free sphingoid base and a ceramid and methods of manufacturing same |
FR2780886B1 (en) * | 1998-07-08 | 2001-06-29 | Jean Noel Thorel | SELF-MOISTURIZING COMPOSITION FOR THE SKIN |
KR100570847B1 (en) * | 1998-09-07 | 2007-12-04 | 주식회사 두산 | Acne skin composition |
US6387382B1 (en) | 1998-11-23 | 2002-05-14 | Axiom Laboratories, Inc. | Water-proof, respirable, skin barrier composition |
GB9918025D0 (en) * | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
GB9918022D0 (en) * | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
KR20010027942A (en) * | 1999-09-16 | 2001-04-06 | 유상옥 | Compositions of lips cosmetics |
FR2799647B1 (en) | 1999-10-15 | 2001-12-07 | Oreal | COMPOSITION IN THE FORM OF A WATER-IN-OIL EMULSION, CONTAINING FIBERS, AND ITS USE IN THE COSMETIC FIELD |
FR2799646B1 (en) * | 1999-10-15 | 2001-12-07 | Oreal | COMPOSITION IN THE FORM OF A WATER-IN-OIL EMULSION, CONTAINING FIBERS, AND ITS USE IN THE COSMETIC FIELD |
FR2811556B1 (en) * | 2000-07-11 | 2002-09-06 | Oreal | COMPOSITION COMPRISING A CERAMIDE PRECURSOR, USE FOR IMPROVING THE NATURAL OR RECONSTRUCTED SKIN, EQUIVALENT OF THE SKIN OBTAINED |
US6372236B1 (en) * | 2000-10-18 | 2002-04-16 | Doosan Corporation | Cream composition for skin care |
JP2002193790A (en) * | 2000-12-27 | 2002-07-10 | Lion Corp | Oil-in-water type emulsion containing scarcely water- soluble drug and method of producing the same |
KR100404072B1 (en) * | 2001-03-12 | 2003-11-03 | 주식회사 두산 | Therapeutic composition for broad spectrum dermal disease |
FR2823671B1 (en) * | 2001-04-23 | 2004-01-09 | Dermaconcept Jmc | DERMATOLOGICAL COMPOSITION COMPRISING NICOTINIC ACID OR AN AMIDE, AND A SPHINGOID BASE |
WO2003049709A1 (en) * | 2001-12-10 | 2003-06-19 | Kao Corporation | Ceramide emulsions |
AU2003224486A1 (en) * | 2002-05-02 | 2003-11-17 | Doosan Corporation | Composition for treating cancer containing n,n-dimethylphytosphingosine |
US20030228337A1 (en) * | 2002-05-29 | 2003-12-11 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Personal care compositions with hydroxy amine neutralized polymers |
US20030224023A1 (en) * | 2002-05-29 | 2003-12-04 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic compositions with hydroxy amine salts of malonic acid |
US20030224027A1 (en) * | 2002-05-29 | 2003-12-04 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic compositions with ammonium malonates |
KR100956698B1 (en) * | 2002-11-19 | 2010-05-06 | 주식회사 두산 | Composition for skin whitening containing N-acetylphytosphingosine |
KR20040048231A (en) * | 2002-12-02 | 2004-06-07 | 주식회사 두산 | Inhibitor of angiogenesis and kit for treating cancer comprising the inhibitor |
AU2003217508A1 (en) * | 2003-03-07 | 2004-09-28 | Korea Atomic Energy Research Institute | A composition comprising phytosphingosine or a derivative thereof |
US20040185074A1 (en) * | 2003-03-17 | 2004-09-23 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Odor control in amine salt containing cosmetic compositions |
US20040202689A1 (en) * | 2003-03-17 | 2004-10-14 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Terpenoid fragrance components stabilized with malonic acid salts |
US20040185073A1 (en) * | 2003-03-17 | 2004-09-23 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic compositions containing salts of malonic acid |
US20040219177A1 (en) * | 2003-04-29 | 2004-11-04 | Jacobs Randy J. | Depleted skin barrier replenishing skin creams composition and method of application |
US20040241131A1 (en) * | 2003-05-29 | 2004-12-02 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Compositions containing malonate salts in preventing in-grown hair arising from shaving |
US7404949B2 (en) * | 2004-03-15 | 2008-07-29 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Methods and compositions useful to prevent in-grown hair arising from shaving |
US20050250732A1 (en) * | 2004-05-07 | 2005-11-10 | The Procter & Gamble Company | Purified, moderately esterified polyol polyester fatty acid compositions |
US20050250733A1 (en) * | 2004-05-07 | 2005-11-10 | The Procter & Gamble Company | Purified, moderately esterified polyol polyester fatty acid compositions |
KR100705054B1 (en) | 2004-06-01 | 2007-04-06 | 주식회사 두산 | Monomethylphytosphingosine and the composition for anti-cancer containing the same |
DE602005004139T2 (en) * | 2005-06-30 | 2009-01-02 | Evonik Goldschmidt Gmbh | Use of salicyloyl sphingoid base for the treatment or prevention of cellulitis |
JP2009519971A (en) * | 2005-12-14 | 2009-05-21 | オルガノジェネシス インク. | Skin care composition and treatment |
US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
CN102438629A (en) * | 2008-07-31 | 2012-05-02 | 花王株式会社 | Ceramide production promoter |
US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
JP2011241228A (en) * | 2011-08-23 | 2011-12-01 | Kishohin Kagaku Kaiho Kenkyusho:Kk | Skin preparation for external use |
MX363386B (en) | 2013-10-03 | 2019-03-20 | Dow Pharmaceutical Sciences | Stabilized efinaconazole compositions. |
JP6389400B2 (en) | 2013-11-21 | 2018-09-12 | 花王株式会社 | Method for producing acetylated sphingoid |
KR102612453B1 (en) | 2013-11-22 | 2023-12-08 | 다우 파마슈티컬 사이언시즈, 인코포레이티드 | Anti-infective methods, compositions, and devices |
CN105939700B (en) | 2014-01-27 | 2020-03-27 | 荷兰联合利华有限公司 | Composition comprising a metal oxide and a metal oxide |
US10004679B2 (en) * | 2014-12-29 | 2018-06-26 | Vidya Herbs, Inc. | Compositions of Amorphophallus konjac and methods for their use in skin care |
WO2018154145A2 (en) * | 2018-03-29 | 2018-08-30 | Symrise Ag | Compounds for skin improvement / treatment |
JP7231344B2 (en) * | 2018-07-10 | 2023-03-01 | 株式会社ダイセル | Ceramide production promoter |
WO2021182419A1 (en) * | 2020-03-09 | 2021-09-16 | 高砂香料工業株式会社 | Ceramide growth promoting agent |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988006034A1 (en) * | 1987-02-13 | 1988-08-25 | Mary Gemma Fiaschetti | Dermal cosmetic composition and applications therefor |
FR2654618A1 (en) * | 1989-11-23 | 1991-05-24 | Sederma Sa | Use in cosmetics of active principles which are intended for regulating cell multiplication |
FR2692781A1 (en) * | 1992-06-24 | 1993-12-31 | Sederma Sa | Cosmetic compsn., for improving skin - contains sphingomyelin(s) of milk or fish as natural precursor ceramide(s), avoiding use of sphingo:lipid(s) from mammals, esp. cattle |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1050756A (en) * | 1964-09-10 | 1900-01-01 | ||
US4294852A (en) * | 1973-11-01 | 1981-10-13 | Johnson & Johnson | Skin treating compositions |
CH629100A5 (en) * | 1979-09-27 | 1982-04-15 | Solco Basel Ag | Hautpraeparat. |
US5342976A (en) * | 1982-06-16 | 1994-08-30 | Elizabeth Arden Co., Division Of Conopco, Inc. | Skin treatment composition |
JPS597118A (en) * | 1982-06-16 | 1984-01-14 | ユニリ−バ−・ナ−ムロ−ゼ・ベンノ−トシヤ−プ | Skin treating composition |
DE3372703D1 (en) * | 1982-10-29 | 1987-09-03 | Crinos Industria Farmaco | Cosmetic preparations promoting the trophism of the skin and of the related hair follicles |
JPS6125160A (en) * | 1984-07-14 | 1986-02-04 | Canon Inc | Image recording device |
JP2544104B2 (en) * | 1985-11-20 | 1996-10-16 | 花王株式会社 | Cosmetics |
AU618517B2 (en) * | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
JPS63192703A (en) * | 1987-02-04 | 1988-08-10 | Kao Corp | External agent for skin |
FR2652002B1 (en) * | 1989-09-21 | 1991-11-29 | Oreal | NOVEL LIPID COMPOUNDS DERIVED FROM SPHINGOSINS, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS, IN PARTICULAR IN COSMETICS AND DERMOPHARMACY. |
AU639373B2 (en) * | 1990-10-22 | 1993-07-22 | Unilever Plc | Cosmetic composition |
JP2743216B2 (en) * | 1990-11-27 | 1998-04-22 | 鐘紡株式会社 | Whitening cosmetics |
FR2673179B1 (en) * | 1991-02-21 | 1993-06-11 | Oreal | CERAMIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS IN COSMETICS AND DERMOPHARMACY. |
JP2964183B2 (en) * | 1991-09-26 | 1999-10-18 | 花王株式会社 | External preparation for skin |
-
1993
- 1993-04-20 GB GB939308103A patent/GB9308103D0/en active Pending
-
1994
- 1994-04-07 NZ NZ265618A patent/NZ265618A/en not_active IP Right Cessation
- 1994-04-07 EP EP94914359A patent/EP0695167B1/en not_active Expired - Lifetime
- 1994-04-07 JP JP52272494A patent/JP3623793B2/en not_active Expired - Lifetime
- 1994-04-07 AU AU66774/94A patent/AU684282B2/en not_active Expired
- 1994-04-07 DE DE69407403T patent/DE69407403T2/en not_active Expired - Lifetime
- 1994-04-07 ES ES94914359T patent/ES2110747T3/en not_active Expired - Lifetime
- 1994-04-07 WO PCT/EP1994/001117 patent/WO1994023694A1/en active IP Right Grant
- 1994-04-19 ZA ZA942678A patent/ZA942678B/en unknown
- 1994-04-20 US US08/230,366 patent/US5578641A/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988006034A1 (en) * | 1987-02-13 | 1988-08-25 | Mary Gemma Fiaschetti | Dermal cosmetic composition and applications therefor |
FR2654618A1 (en) * | 1989-11-23 | 1991-05-24 | Sederma Sa | Use in cosmetics of active principles which are intended for regulating cell multiplication |
FR2692781A1 (en) * | 1992-06-24 | 1993-12-31 | Sederma Sa | Cosmetic compsn., for improving skin - contains sphingomyelin(s) of milk or fish as natural precursor ceramide(s), avoiding use of sphingo:lipid(s) from mammals, esp. cattle |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0716589A1 (en) * | 1993-07-23 | 1996-06-19 | Morris Herstein | Cosmetic, skin-renewal stimulating composition with long-term irritation control |
EP0716589A4 (en) * | 1993-07-23 | 1997-06-11 | Morris Herstein | Cosmetic, skin-renewal stimulating composition with long-term irritation control |
US5607921A (en) * | 1994-01-31 | 1997-03-04 | L'oreal | Stabilized cosmetic or dermatological composition containing several precursors of the same active agent in order to maximize its release, and use thereof |
WO1996016635A1 (en) * | 1994-11-28 | 1996-06-06 | Gist-Brocades B.V. | Topical application of ceramides |
DE19518815A1 (en) * | 1995-05-23 | 1996-11-28 | Beiersdorf Ag | Cosmetic or dermatological preparations containing alpha-hydroxy fatty acids |
WO1996037192A1 (en) * | 1995-05-26 | 1996-11-28 | Vesifact Ag | Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids |
WO1997014401A1 (en) * | 1995-10-16 | 1997-04-24 | Kao Corporation | Skin and hair cosmetic compositions |
US6348200B1 (en) * | 1995-10-16 | 2002-02-19 | Kao Corporation | Cosmetic composition |
EP0790053A1 (en) * | 1996-02-15 | 1997-08-20 | L'oreal | Use of 2-amino-alkane-1,3-diol to reduce hairloss and/or to induce and stimulate hairgrowth |
FR2744916A1 (en) * | 1996-02-15 | 1997-08-22 | Oreal | USE OF A 2-AMINO-ALCANE-1,3-DIOL AS AN AGENT FOR BRAKING HAIR LOSS AND / OR INDUCING AND STIMULATING THEIR GROWTH |
US6184252B1 (en) | 1996-02-15 | 2001-02-06 | Societe L'oreal S.A. | 2-amino-1,3-alkanediol compositions for inducing/stimulating hair growth and/or retarding hair loss |
US5955092A (en) * | 1996-09-27 | 1999-09-21 | Elizabeth Arden Co., Division Of Conopco, Inc. | Skin care compositions containing an n-substituted fatty acid amide and retinol or retinyl ester |
WO1998013018A1 (en) * | 1996-09-27 | 1998-04-02 | Unilever Plc | Skin care composition containing an amide and retinol or retinyl ester |
US5932233A (en) * | 1996-11-07 | 1999-08-03 | Kao Corporation | Cosmetic compositions |
EP0842655A2 (en) * | 1996-11-14 | 1998-05-20 | Kao Corporation | Water-in-oil type cosmetic emulsion containing amide derivatives |
US5925365A (en) * | 1996-11-14 | 1999-07-20 | Kao Corporation | Water-in-oil cosmetic emulsions |
EP0842655A3 (en) * | 1996-11-14 | 1999-01-07 | Kao Corporation | Water-in-oil type cosmetic emulsion containing amide derivatives |
WO1999007337A1 (en) * | 1997-08-07 | 1999-02-18 | L'oreal | Use of a 2-amino-alkane polyol as agent for treating skin ageing signs |
FR2767056A1 (en) * | 1997-08-07 | 1999-02-12 | Oreal | USE OF A 2-AMINO-ALKANE POLYOL AS AN AGENT FOR TREATING THE SIGNS OF SKIN AGING |
WO1999047114A1 (en) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Moisturizing compositions |
EP1287815A1 (en) * | 2001-08-31 | 2003-03-05 | Cosmoferm B.V. | Use of a sphingoid base for inhibiting ceramidase activity |
US7737186B2 (en) | 2002-03-01 | 2010-06-15 | Lvmh Recherche | Cosmetic use of phytosphingosine as slimming agent and cosmetic compositions comprising phytosphingosine |
CN103764108A (en) * | 2011-08-03 | 2014-04-30 | 赢创德固赛有限公司 | Use of sphinganine to improve the visual appearance of skin and hair |
US9610232B2 (en) | 2011-08-03 | 2017-04-04 | Evonik Degussa Gmbh | Use of sphinganine to improve the visual appearance of skin and hair |
WO2013017361A1 (en) * | 2011-08-03 | 2013-02-07 | Evonik Goldschmidt Gmbh | Use of sphinganine to improve the visual appearance of skin and hair |
CN103917217A (en) * | 2011-10-31 | 2014-07-09 | 赢创工业集团股份有限公司 | Cosmetic formulation |
WO2013064388A3 (en) * | 2011-10-31 | 2013-07-11 | Evonik Industries Ag | Cosmetic formulation containing n-acyl-phytosphingosine |
CN102702894B (en) * | 2012-06-18 | 2014-04-23 | 中国船舶重工集团公司第七二五研究所 | Sphingosine derivative anti-fouling agent and preparation method thereof |
CN102702894A (en) * | 2012-06-18 | 2012-10-03 | 中国船舶重工集团公司第七二五研究所 | Sphingosine derivative anti-fouling agent and preparation method thereof |
WO2019185038A1 (en) * | 2018-03-29 | 2019-10-03 | 中国医学科学院基础医学研究所 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid |
CN111918672A (en) * | 2018-03-29 | 2020-11-10 | 中国医学科学院基础医学研究所 | Artificially synthesized sphingosine derivative lipid monomer and application thereof in delivering nucleic acid |
CN111918672B (en) * | 2018-03-29 | 2023-08-08 | 中国医学科学院基础医学研究所 | Artificially synthesized sphingosine derivative lipid monomer and application thereof in nucleic acid delivery |
Also Published As
Publication number | Publication date |
---|---|
JPH08508742A (en) | 1996-09-17 |
GB9308103D0 (en) | 1993-06-02 |
DE69407403T2 (en) | 1998-04-09 |
JP3623793B2 (en) | 2005-02-23 |
EP0695167B1 (en) | 1997-12-17 |
US5578641A (en) | 1996-11-26 |
EP0695167A1 (en) | 1996-02-07 |
NZ265618A (en) | 1997-07-27 |
ES2110747T3 (en) | 1998-02-16 |
AU6677494A (en) | 1994-11-08 |
ZA942678B (en) | 1995-10-19 |
AU684282B2 (en) | 1997-12-11 |
DE69407403D1 (en) | 1998-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0695167B1 (en) | Cosmetic composition containing ceramide precursors | |
US6270780B1 (en) | Cosmetic compositions containing resveratrol | |
DE60031872T2 (en) | COSMETIC COMPOSITIONS CONTAINING RESVERATROL AND RETINOIDES | |
US5476661A (en) | Compositions for topical application to skin, hair and nails | |
US6521239B1 (en) | Cosmetic composition containing at least one auxin and its use | |
US5206020A (en) | Synthetic pseudoceramide and cosmetic compositions thereof | |
US5208355A (en) | Cosmetic composition | |
JP2718639B2 (en) | Cosmetic and / or dermatological composition for aging treatment containing ceramides and method of using the same | |
JP2006070048A (en) | Application of ascorbic acid derivatives for augmenting the synthesis of epidermal ceramides | |
CA2266048C (en) | Topical composition and method for enhancing lipid barrier synthesis | |
KR19980019155A (en) | Irritating seed oil of irritation in hydroxy acid or retinoid containing compositions | |
DE60028071T2 (en) | COSMETIC AGENTS CONTAINING PEPPER EXTRACT AND RETINOIDS | |
EP0587288B1 (en) | Cosmetic composition containing a lipid and a hydroxy or ketocarboxylic acid | |
JP3431425B2 (en) | Cosmetic composition containing tricholine citrate | |
US6264962B1 (en) | Use of cinnamic acid or of at least one of its derivatives in a cosmetic composition | |
CA2159201C (en) | Cosmetic composition | |
KR100666512B1 (en) | Cosmetic Skin Care Compositions Containing Cumic Alcohol | |
JP3703904B2 (en) | Skin moisturizer | |
AU2002220694B2 (en) | Cosmetic method of treating skin | |
US20020006420A1 (en) | Use of a 2-amino-alkane polyol as agent for treating skin ageing signs | |
JPH06271446A (en) | Wrinkle improver | |
KR20040087443A (en) | Cosmetic Composition for Improving Skin Condition Comprising Solanum Tuberosum Extract as Active Ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994914359 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2159201 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 265618 Country of ref document: NZ |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 1994914359 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994914359 Country of ref document: EP |